Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kiyean Nam"'
Autor:
Do-Youn Oh, Seung-Tae Kim, Sun Young Rha, Anthony El-Khoueiry, Hong Jae Chon, Jaspreet Grewal, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam, Baek-Yeol Ryoo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ec1c164f909d43019e62a0cb0a2eb0bb
Autor:
Angela Alistar, Alain Mita, Devalingam Mahalingam, Anthony El-Khoueiry, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7b62f76ff37b4f64b88e92009cae8e48
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 167, Iss , Pp 115441- (2023)
Telacebec is a new anti-tuberculosis agent with promising therapeutic activity and a favorable safety profile. This study aimed to characterize the pharmacokinetics of telacebec via interspecies scaling and population pharmacokinetic modeling for the
Externí odkaz:
https://doaj.org/article/378b4a65abc24722af03661f79d0571e
Autor:
DongHoon Yu, Sabrina Wagner, Martin Schütz, Yeejin Jeon, Mooyoung Seo, Jaeseung Kim, Nadine Brückner, Jintawee Kicuntod, Julia Tillmanns, Christina Wangen, Friedrich Hahn, Benedikt B. Kaufer, Frank Neipel, Jan Eickhoff, Bert Klebl, Kiyean Nam, Manfred Marschall
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 158 (2024)
The repertoire of currently available antiviral drugs spans therapeutic applications against a number of important human pathogens distributed worldwide. These include cases of the pandemic severe acute respiratory coronavirus type 2 (SARS-CoV-2 or C
Externí odkaz:
https://doaj.org/article/bc65e804ec3a43f1ab41539356429fa9
Autor:
Jeongjun Kim, Jinho Choi, Hwankyu Kang, Jiye Ahn, Jane Hutchings, Christo van Niekerk, Jaeseung Kim, Yeejin Jeon, Kiyean Nam, Tae Hwan Kim, Beom Soo Shin, Soyoung Shin
Publikováno v:
Antimicrob Agents Chemother
A phase 1b, randomized, placebo-controlled, double-blind, multiple ascending dose study (NCT02858973) was conducted to assess the safety, tolerability, and pharmacokinetics of the new antituberculosis agent telacebec (Q203). A total of 47 healthy adu
Autor:
Yeejin Jeon, Hwankyu Kang, Yeongin Yang, Dongsik Park, Baejung Choi, Jeongjun Kim, Jaeseung Kim, Kiyean Nam
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4821
Although immune checkpoint blockade (ICB) represents a major breakthrough in cancer immunotherapy, only a limited number of patients with cancer benefit from ICB-based immunotherapy because most immune checkpoint inhibitors (ICIs) target only T cell
Autor:
Bae Jung Choi, Devalingam Devalingam, Angela Alistar, Anthony El-Khoueiry, Alain Mita, Hwankyu Kang, Jinho Choi, Hyunji Ahn, Jeongjun Kim, Seung-Joo Lee, Yeong-In Yang, Jiye Ahn, Borami Jeon, Jaeseung Kim, Kiyean Nam
Publikováno v:
Cancer Research. 83:2255-2255
Background: Axl, Mer and CSF1 receptor tyrosine kinases play vital roles in promoting the immunosuppressive tumor microenvironment (TME) by affecting myeloid functions (e.g., tumor associated macrophage [TAM], myeloid derived suppression cell [MDSC])
Autor:
Donghoon Yu, Yeejin Jeon, YoonJi Lee, Seung-Joo Lee, Jaeseung Kim, Hyerim Jung, Tae-Kyung Kim, Kiyean Nam
Publikováno v:
Cancer Research. 83:5977-5977
Background; Q901 is an extremely selective CDK7 inhibitor with potent single agent activity in the multiple in vivo tumor models including small cell lung cancer, cholangiocarcinoma, colon cancer, pancreatic cancer, hormone receptor positive breast c
Autor:
Jane Hutchings, Kiyean Nam, Dongsik Park, Jeon Yeejin, Beom Soo Shin, Christo van Niekerk, Jaeseung Kim, Jeongjun Kim, Soyoung Shin, Hwankyu Kang, Jinho Choi, Ahn Jiye
Publikováno v:
Antimicrob Agents Chemother
Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001
Publikováno v:
Cancer Research. 82:2574-2574
As a key regulator of its dual role in transcription and cell cycle progression, CDK7 has been determined to be an attractive therapeutic target in a variety of tumor types driven by cell cycle dysregulation and aberrant control of the transcriptiona